Skip to main content
. 2018 Aug 21;20(11):2690–2694. doi: 10.1111/dom.13444

Figure 2.

Figure 2

Severity of nausea, vomiting and diarrhoea with iGlarLixi in A, LixiLan‐L and B, LixiLan‐O. AE, adverse event; GI, gastrointestinal. The pie charts show the percentage of patients with/without a GI AE; the bars show the percentage of events (i.e. one patient can contribute with multiple events)